ArticleJournal of the National Cancer Institute2025
Germline rare variants in cancer susceptibility genes and subsequent neoplasm risk after childhood cancer.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAmong childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes could increase the risk of subsequent neoplasms, but risks for rarer subsequent neoplasms and by age at onset are not well understood.
methodsWe pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years [range = 7.1-55.6 years]) to identify rare deleterious germline variants across 150 literature-based cancer susceptibility genes using the ClinVar (National Library of Medicine) and SnpEff tools. Conditional logistic regression evaluated overall and subsequent neoplasm-specific risk, matching up to 100 subsequent neoplasm-free control individuals to participants by age, sex, childhood cancer type, radiation dose, chemotherapy, study, and follow-up time.
resultsAmong 11 840 survivors, 2165 (18.3%) developed 1 or more subsequent neoplasms. Overall subsequent neoplasm risk was modestly increased for variant carriers in any autosomal dominant cancer susceptibility gene (288/2165 [13.3%] cases; 9.9% of control individuals; odds ratio [OR] = 1.4, 95% CI = 1.3 to 1.6; P = 5.0 × 10-7). Carriers of variants in cancer-specific autosomal dominant cancer susceptibility genes had higher subsequent neoplasm risks, particularly for glioma (OR = 20.4, 95% CI = 7.4 to 56.1; P = 2.7 × 10-10), colorectal cancer (OR = 5.9, 95% CI = 1.4 to 25.7; P = 9.1 × 10-3), bone/soft-tissue sarcoma (OR = 5.3, 95% CI = 2.2 to 12.7; P = 1.5 × 10-3), meningioma (OR = 4.0, 95% CI = 1.4 to 1.0; P = 3.2 × 10-3), basal cell carcinoma (OR = 3.5, 95% CI = 1.2 to 10.0; P = .020), and breast cancer (OR = 2.6, 95% CI = 1.8 to 3.9; P = 2.8 × 10-6), who were also more likely to develop such subsequent neoplasms at younger ages. Notably, all meningioma, sarcoma, and glioma subsequent neoplasms among carriers occurred before ages 20, 25, and 35 years, respectively.
conclusionsSurvivors with rare germline variants in cancer-specific autosomal dominant cancer susceptibility genes had increased subsequent neoplasm risk, especially at younger ages. These findings offer a potential basis for enhancing risk-stratified long-term surveillance for childhood cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.